Curcumin C3 Reduct (R): The First to Deliver Curcumin as a Metabolite (Only EFSA approved Curcumin metabolite)

Curcumin C3 Reduct® is Sabinsa’s next-generation curcumin standardized to ≥95% tetrahydrocurcuminoids (THCs)—the biologically active metabolites the body actually uses. By delivering THCs directly, it bypasses first-pass conversion and provides a cleaner, more predictable performance profile than native curcumin. Why it matters (one line) Curcumin’s benefits without curcumin’s baggage: no color, no taste, better stability, and a clear EU Novel Food pathway for faster, lower-risk launches. Mechanism & science Metabolite-first design: THCs are readily absorbed and biologically active, aligning in-vitro promise with in-use outcomes. Cascading antioxidant action: Supports modulation of oxidative and inflammatory stress relevant to recovery and healthy aging. AMPK linkage: Evidence of AMPK activation underpins narratives in metabolic efficiency, weight-management support, and post-exercise recovery (claims per jurisdiction). Formulation advantages Sensory neutrality: Colorless and taste-neutral, enabling white tablets, pastel gummies, clear or lightly tinted beverages, and multi-actives without staining or heavy masking. pH stability: Superior behavior across a broader pH range than curcumin/DMC/BDMC supports predictable shelf performance. Reproducibility: Standardization to ≥95% THCs improves batch-to-batch consistency and QC. Format breadth: Capsules, tablets, powders/sticks, gummies, beverages, and complex blends—all with fewer trade-offs. Regulatory & quality EU Novel Food status: First EFSA-approved curcumin metabolite—strong dossier, smoother commercialization, cleaner label/claims hygiene in Europe. Where it plays best Active lifestyle & sports: Post-exercise recovery via oxidative/inflammatory stress modulation. Metabolic concepts: AMPK-linked energy utilization and weight-management support. Healthy aging & cognitive: Antioxidant/anti-inflammatory profile fits long-horizon wellness architectures. Organ-health exploration: Room for evidence-led expansion with disciplined claims. Competitive edge Versus native/“enhanced” curcumin: No pigment, fewer sensory fixes, broader pH tolerance, and metabolite-level logic rather than delivery workarounds. Versus commodity options: Proprietary standardization, strong regulatory footing, and scalable manufacturability. Slide-ready talking points Metabolites, not make-do. Formulation freedom (colorless, taste-neutral, pH-stable). Compliance made simpler (EU Novel Food). Platform ingredient across formats and categories. Bottom line Curcumin C3 Reduct® turns curcumin into a scale-ready platform: body-ready metabolites, clean sensory profile, broad pH stability, and first-in-class EU status—enabling faster development, attractive products, and durable compliance stories.

Lingua della presentazione: English